NIPA1 Antibody (E-4): sc-398041

NIPA1 Antibody (E-4) is a mouse monoclonal IgM antibody that detects NIPA1 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-NIPA1 antibody (E-4) is available as the non-conjugated form. NIPA1, also known as non-imprinted in Prader-Willi/Angelman syndrome 1, SPG6, or FSP3, is a 329 amino acid multi-pass membrane protein that exists in multiple alternatively spliced isoforms and is predominantly expressed in neuronal tissue. NIPA1′s structure facilitates function in the nervous system, where NIPA1 is believed to play a significant role in neuronal development and signaling. Defects in NIPA1 can lead to spastic paraplegia autosomal dominant type 6 (SPG6), a debilitating condition characterized by progressive weakness in the lower limbs due to degeneration of the spinal cord. The gene encoding NIPA1 is located on human chromosome 15, a region associated with several genetic disorders, including Angelman syndrome and Prader-Willi syndrome, highlighting NIPA1′s importance in both normal physiology and disease pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NIPA1 Antibody (E-4) References:

1. Identification of four highly conserved genes between breakpoint hotspots BP1 and BP2 of the Prader-Willi/Angelman syndromes deletion region that have undergone evolutionary transposition mediated by flanking duplicons.  |  Chai, JH., et al. 2003. Am J Hum Genet. 73: 898-925. PMID: 14508708
2. NIPA1 gene mutations cause autosomal dominant hereditary spastic paraplegia (SPG6).  |  Rainier, S., et al. 2003. Am J Hum Genet. 73: 967-71. PMID: 14508710
3. Distinct novel mutations affecting the same base in the NIPA1 gene cause autosomal dominant hereditary spastic paraplegia in two Chinese families.  |  Chen, S., et al. 2005. Hum Mutat. 25: 135-41. PMID: 15643603
4. A novel NIPA1 mutation associated with a pure form of autosomal dominant hereditary spastic paraplegia.  |  Reed, JA., et al. 2005. Neurogenetics. 6: 79-84. PMID: 15711826
5. The role of hereditary spastic paraplegia related genes in multiple sclerosis. A study of disease susceptibility and clinical outcome.  |  DeLuca, GC., et al. 2007. J Neurol. 254: 1221-6. PMID: 17420921
6. Screening of hereditary spastic paraplegia patients for alterations at NIPA1 mutational hotspots.  |  Beetz, C., et al. 2008. J Neurol Sci. 268: 131-5. PMID: 18191948
7. Autosomal dominant familial spastic paraplegia: tight linkage to chromosome 15q.  |  Fink, JK., et al. 1995. Am J Hum Genet. 56: 188-92. PMID: 7825577
8. Autosomal dominant, familial spastic paraplegia, type I: clinical and genetic analysis of a large North American family.  |  Fink, JK., et al. 1995. Neurology. 45: 325-31. PMID: 7854534

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NIPA1 Antibody (E-4) has 0 citations in a variety of scientific publications.

Primary antibodies like Anti-NIPA1 Antibody (E-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NIPA1 Antibody (E-4) Specifications

Alternate Product Name: NIPA1

Product Clone Name: E-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgM kappa light chain

Amino Acids: 210-229

Epitope Target: NIPA1

Epitope Species: human

Product Reactivity/Detection: NIPA1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgM kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 0 citations in various scientific publications

Available Conjugates/Forms for NIPA1 Antibody (E-4): P: Blocking Peptide